Enzyme Mechanism Elucidation
Probe the role of specific hydrogen bonds or electrostatic contributions in catalysis by replacing canonical residues with pKa-tuned polar ncAA analogs.
Harnessing the power of genetic code expansion (GCE) technology enables the site-specific incorporation of non-canonical amino acids (ncAAs) into proteins, opening vast avenues for protein engineering and synthetic biology. Small polar ncAAs, characterized by their low molecular volume and high polarity, are potent tools. They introduce critical chemical functionalities, such as hydroxyl, amino, or amide groups, into proteins with minimal structural perturbation, enabling precise modulation of protein properties. As a leader integrating a proprietary high-throughput GCEngine platform with comprehensive preclinical expertise, we deliver end-to-end solutions for reliable and efficient small polar ncAA incorporation, empowering your research and therapeutic programs.
Small polar ncAAs (e.g., serine/threonine analogs, fluorinated derivatives) are defined by their compact size and significant polarity. They serve as critical tools for modulating local protein microenvironments, fine-tuning electrostatic potentials, hydrogen-bonding networks, and solvation, without causing steric clashes. Their incorporation typically involves reassigning a stop codon (e.g., the amber codon, TAG) or other engineered codons to encode these synthetic building blocks. This process requires an orthogonal aminoacyl-tRNA synthetase (aaRS) and its cognate tRNA (tRNA) pair, which functions independently of the host's native translation machinery to ensure fidelity. A central challenge lies in engineering the aaRS to exquisitely discriminate between the target small polar ncAA and structurally similar endogenous amino acids, thereby preventing mis-incorporation and achieving high-precision protein modification.
Fig.1 Structural analysis of MmSerRS enables engineering of its orthogonal system for small, polar ncAA incorporation. (Zambaldo, C., et al., 2020)
Enzyme Mechanism Elucidation
Probe the role of specific hydrogen bonds or electrostatic contributions in catalysis by replacing canonical residues with pKa-tuned polar ncAA analogs.
Biopharmaceutical Optimization
Improve the solubility, stability, and PK properties of therapeutic proteins (e.g., antibodies, cytokines) by strategically incorporating polar ncAAs on solvent-exposed surfaces.
Protein-Protein Interaction (PPI) Mapping
Utilize polar ncAAs to stabilize transient complexes, install photochemical crosslinkers, or create "caged" residues for spatiotemporal control of interactions.
Advanced Biomaterial Synthesis
Engineer bio-polymers or self-assembling peptides with precisely controlled hydration, adhesion, or mechanical properties for tissue engineering and drug delivery applications.
Leveraging a proprietary, high-throughput GCEngine platform, a comprehensive suite of services is provided to overcome the challenges associated with small polar ncAA incorporation. This integrated approach covers the entire pipeline, from the identification and optimization of robust orthogonal aaRS/tRNA pairs tailored to the client's specific ncAA, through rigorous in vitro validation, to successful implementation in live-cell systems for protein production or cellular studies. This end-to-end support accelerates timelines and de-risks the development of novel protein-based tools and therapeutics.
Small polar ncAAs possess compact side chains with hydrogen-bonding or dipolar character. They enable the subtle, localized modulation of protein properties, such as electrostatics, solubility, and conformational dynamics, while minimizing disruptions to the overall protein fold. Our platform supports the incorporation of a diverse array of small polar ncAAs, each category designed to address specific protein engineering goals.
Hydroxyl-Containing Analogs
Residues such as α-methyl-serine and β-hydroxynorvaline introduce sterically constrained hydroxyl groups with altered pKa or rotameric preferences, useful for probing proton transfer pathways or improving metabolic stability in peptide therapeutics.
Aliphatic Fluorinated Polar Residues
Examples like 4-fluorothreonine leverage the high electronegativity of fluorine to fine-tune hydrogen-bond strength and local polarity while maintaining a small footprint, valuable for ¹⁹F NMR studies and optimizing ligand-binding interfaces.
Short-Chain Diamino or Amino Alcohol Derivatives
Building blocks like 2,3-diaminopropionic acid (Dap) or serinol analogs provide multiple hydrogen-bonding sites within a minimal framework, enabling precise engineering of catalytic sites or protein solvation shells.
Polar Isosteres of Canonical Residues
Compact mimics such as thiazole alanine (a serine isostere) or oxazole-containing glycine analogs mimic native polarity while introducing enhanced rigidity, metabolic stability, or resistance to degradation.
Beyond standard offerings, tailored solutions are available to meet unique project requirements:
Custom Orthogonal Pair Development
De novo design and evolution of aaRS/tRNA pairs for proprietary or novel small polar ncAAs, utilizing computational design, directed evolution, and our high-throughput screening platform.
Stable Cell Line Engineering
Generation of clonal cell lines, spanning bacterial, yeast, and mammalian systems, that are genetically optimized for consistent, high-fidelity incorporation of small polar ncAAs over extended culture periods.
Multi-site Incorporation
Development of orthogonal translation systems capable of simultaneously incorporating one or more small polar ncAAs at multiple sites within a single protein.
Comprehensive Analytical Characterization
Full quality control support, including high-resolution mass spectrometry to confirm site-specific incorporation, occupancy rates, and protein integrity.
Successfully incorporating small polar ncAAs requires a blend of specialized technology, experienced execution, and a partner committed to advancing your research or therapeutic goals. Our dedicated platform and team provide a reliable path to achieve precise protein modifications with these versatile tools. To explore how our GCEngine platform and small polar ncAA incorporation services can empower your next project in synthetic biology or biotherapeutics development, please reach out to our scientific team for a detailed consultation.
All our services are exclusively intended for preclinical research purposes. They are not intended for diagnostic, therapeutic, or patient management applications.
A specialized platform advancing genetic code expansion through orthogonal tRNA/aaRS technologies, enabling precise ncAA incorporation for biotherapeutic development, synthetic biology, and diagnostics.